Loading…

Medical Research Finder

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

Brentuximab vedotin & Peripheral T-cell lymphoma

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Brentuximab vedotin is approved by FDA and EMA for systemic anaplastic large cell lymphoma (sALCL), a subtype of Peripheral T-cell lymphoma, after failure of at least one prior multi-agent chemotherapy regimen.

Gravanis et al. 2016 Oncologist 21(1): 102-9

…

FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell Lymphoma
Richardson et al. 2019
The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use
Gravanis et al. 2016 Oncologist 21(1): 102-9

7/1/2026